You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 132 No. 8, August 1997 TABLE OF CONTENTS
  Archives
  •  Online Features
  ARTICLE
 This Article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal

Frequency and duration of remission after isolated limb perfusion for melanoma

J. F. Thompson, J. A. Hunt, K. F. Shannon and P. C. Kam
Sydney Melanoma Unit, Royal Prince Alfred Hospital, Australia. john@mel.rpa.cs.nsw.gov.au

OBJECTIVE: To examine the frequency and duration of complete remission for locally recurrent and metastatic limb melanoma after isolated limb perfusion (ILP) with cytotoxic agents. DESIGN: A case series of 114 consecutive therapeutic ILPs performed between April 1984 and April 1994 and a review of previously published studies. SETTING: A tertiary referral center for melanoma treatment, located at a university teaching hospital. RESULTS: Of 111 assessable ILPs, 81 (73%) resulted in complete limb tumor remission and 14 (13%) resulted in partial remission (defined as a reduction in size of tumor deposits by > 50%). Complete remission was maintained in 37 (46%) of the 81 cases without any further treatment (median follow-up, 33 months; range, 8-112 months). Of the other 44 cases, disease subsequently recurred in the perfused limb (median time to recurrence, 9.5 months; range, 2-65 months). In 19 of these cases, however, the limb was again disease free at last follow-up after local surgery (12 cases) or a repeat ILP (7 cases). Overall, complete locoregional control was achieved after 50% of assessable ILPs, and a long-term disease-free state in the limb was achieved, with or without further treatment, in 56 (69%) of the 81 cases in which an initial complete remission occurred. For 743 therapeutic ILPs undertaken in 12 series previously reported in the literature, an initial complete remission was reported in 50% of these cases and partial remission in 32%. CONCLUSION: Therapeutic ILP is an effective form of treatment for patients with recurrent and metastatic limb melanoma, achieving short- and long-term results that are superior to those achievable by any other form of treatment currently used.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Isolated Limb Infusion for In-Transit Malignant Melanoma of the Extremity: A Well-Tolerated but Less Effective Alternative to Hyperthermic Isolated Limb Perfusion
Beasley et al.
Ann. Surg. Oncol. 2008;15:2195-2205.
ABSTRACT | FULL TEXT  

A Phase II Trial of Isolated Limb Infusion With Melphalan and Dactinomycin for Regional Melanoma and Soft Tissue Sarcoma of the Extremity
Brady et al.
Ann. Surg. Oncol. 2006;13:1123-1129.
ABSTRACT | FULL TEXT  

Efficacy of Repeat Isolated Limb Perfusions With Tumor Necrosis Factor {alpha} and Melphalan for Multiple In-Transit Metastases in Patients with Prior Isolated Limb Perfusion Failure
Grunhagen et al.
Ann. Surg. Oncol. 2005;12:609-615.
ABSTRACT | FULL TEXT  

Prognostic Factors After Isolated Limb Infusion With Cytotoxic Agents for Melanoma
Lindner et al.
Ann. Surg. Oncol. 2002;9:127-136.
ABSTRACT | FULL TEXT  

Loss of MDA-7 Expression With Progression of Melanoma
Ellerhorst et al.
JCO 2002;20:1069-1074.
ABSTRACT | FULL TEXT  

Isolated Limb Perfusion in the Management of Patients With Recurrent Limb Melanoma: An Important but Limited Role
Thompson and de Wilt
Ann. Surg. Oncol. 2001;8:564-565.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1997 American Medical Association. All Rights Reserved.